Severe Liver Cirrhosis Markedly Reduces AhR-Mediated Induction of Cytochrome P450 in Rats by Decreasing the Transcription of Target Genes

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Floreani, Maura ^a   De Martin, Sara ^a   Gabbia, Daniela ^a   Barbierato, Massimo ^a   Nassi, Alberto ^a   Mescoli, Claudia ^a   Orlando, Rocco ^a   Bova, Sergio ^a   Angeli, Paolo ^a   Gola, Elisabetta ^a   Sticca, Antonietta ^a   Palatini, Pietro ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; BENZO[A]PYRENE; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; MESSENGER RNA; CYP1A2 PROTEIN, RAT; CYTOCHROME;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASCITES; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME INDUCTION; GENE EXPRESSION; LIVER CIRRHOSIS; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; TRANSCRIPTION REGULATION; ANIMAL; CHEMICALLY INDUCED; ENZYMOLOGY; EXPERIMENTAL LIVER CIRRHOSIS; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; LIVER; LIVER FUNCTION TEST; METABOLISM; PATHOLOGY; SEVERITY OF ILLNESS INDEX; WISTAR RAT;

RATTUS;

ANIMALS; ASCITES; BENZO(A)PYRENE; CYTOCHROME P-450 CYP1A1; CYTOCHROMES; ENZYME INDUCTION; GENE EXPRESSION REGULATION; LIVER; LIVER CIRRHOSIS, EXPERIMENTAL; LIVER FUNCTION TESTS; MALE; RATS; RATS, WISTAR; RECEPTORS, ARYL HYDROCARBON; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; TRANSCRIPTION, GENETIC;

EID: 84876539761     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0061983     Document Type: Article

References (36)

1. Tucker GT, Houston JB, Huang SM, (2001) Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential-toward a consensus. Clin Pharmacol Ther 70: 103-114.
2. Park BK, Kitteringham NR, Pirmohamed M, Tucker GT, (1996) Relevance of induction of human drug-metabolizing enzymes: pharmacological and toxicological implications. Br J Clin Pharmacol 41: 477-491.
3. Fuhr U, (2000) Induction of drug metabolising enzymes: pharmacokinetic and toxicological consequences in humans. Clin Pharmacokinet 38: 493-504.
4. Orlando R, Piccoli P, De Martin S, Padrini R, Floreani M, et al. (2004) Cytochrome P450 1A2 is a major determinant of lidocaine metabolism in vivo: effects of liver function. Clin Pharmacol Ther 75: 80-88.
5. Orlando R, Padrini R, Perazzi M, De Martin S, Piccoli P, et al. (2006) Liver dysfunction markedly decreases the inhibition of cytochrome P450 1A2-mediated theophylline metabolism by fluvoxamine. Clin Pharmacol Ther 79: 489-499.
6. Orlando R, De Martin S, Pegoraro P, Quintieri L, Palatini P, (2009) Irreversible CYP3A inhibition accompanied by plasma protein-binding displacement: a comparative analysis in subjects with normal and impaired liver function. Clin Pharmacol Ther 85: 319-326.
7. Palatini P, Orlando R, De Martin S, (2010) The effect of liver disease on inhibitory and plasma protein-binding displacement interactions: an update. Expert Opin Drug Metab Toxicol 6: 1215-1230.
8. Hoyumpa AM Jr, Schenker S, (1982) Major drug interactions: effect of liver disease, alcohol, and malnutrition. Annu Rev Med 33: 113-149.
9. Elbekai RH, Korashy HM, El-Kadi AO, (2004) The effect of liver cirrhosis on the regulation and expression of drug metabolizing enzymes. Curr Drug Metab 5: 157-167.
10. Palatini P, De Martin S, Pegoraro P, Orlando R, (2008) Enzyme inhibition and induction in liver disease. Curr Clin Pharmacol 3: 56-69.
11. Farrell GC, Zaluzny L, (1984) Microsomal protein synthesis and induction of cytochrome P-450 in cirrhotic rat liver. Aust J Exp Biol Med Sci 62: 291-301.
12. Wu ZQ, Piché D, Vallières S, Huet PM, Gascon-Barré M, (1991) Unimpaired induction of drug-metabolizing enzymes in hepatocytes isolated from rats with micronodular cirrhosis. Can J Physiol Pharmacol 69: 426-436.
13. Marshall WJ, McLean AE, (1969) The effect of cirrhosis of the liver on microsomal detoxications and cytochrome P-450. Br J Exp Pathol 50: 578-583.
14. Jiménez W, Martinez-Pardo A, Arroyo V, Bruix J, Rimola A, et al. (1985) Temporal relationship between hyperaldosteronism, sodium retention and ascites formation in rats with experimental cirrhosis. Hepatology 5: 245-250.
15. Jiménez W, Clária J, Arroyo V, Rodés J, (1992) Carbon tetrachloride induced cirrhosis in rats: a useful tool for investigating the pathogenesis of ascites in chronic liver disease. J Gastroenterol Hepatol 7: 90-97.
16. Nebert DW, Dalton TP, Okey AB, Gonzales FJ, (2004) Role of Aryl Hydrocarbon Receptor-mediated induction of CYP1 enzymes in environmental toxicity and cancer. J Biol Chem 279: 23847-23850.
17. Da Rosa DP, Bona S, Simonetto D, Zettler C, Marroni CA, et al. (2010) Melatonin protects the liver and erythrocytes against oxidative stress in cirrhotic rats. Arq Gastroenterol 47: 72-78.
18. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, et al. (1995) Histological grading and staging of chronic hepatitis. J Hepatol 22: 696-699.
19. Pearce RE, McIntyre CJ, Madan A, Sanzgiri U, Draper AJ, et al. (1996) Effects of freezing, thawing, and storing human liver microsomes on cytochrome P450 activity. Arch Biochem Biophys 331: 145-169.
20. Omura T, Sato R, (1964) The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239: 2370-2378.
21. Floreani M, Gabbia D, Barbierato M, De Martin S, Palatini P, (2012) Differential inducing effect of benzo[a]pyrene on gene expression and enzyme activity of cytochromes P450 1A1 and 1A2 in Sprague-Dawley and Wistar rats. Drug Metab Pharmacokinet 27: 640-652.
22. Laemmli UK, (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227: 680-685.
23. Hanioka N, Tatarazako N, Jinno H, Arizono K, Ando M (2000) Determination of cytochrome P450 1A activities in mammalian liver microsomes by high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 744: 399-406.
24. Copeland RA (2000) Enzymes. A Practical Introduction to Structure, Mechanisms and Data Analysis. New York: John Wiley and Sons, Inc., 397 p.
25. Burke MD, Thompson S, Weaver RJ, Wolf CR, Mayer RT, (1994) Cytochrome P450 specificities of alkoxyresorufin O-dealkylation in human and rat liver. Biochem Pharmacol 48: 923-936.
26. Rendic S, Di Carlo FJ, (1997) Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29: 413-580.
27. Shimada T, Yamazaki H, Mimura M, Wakamiya N, Ueng WF, et al. (1996) Characterization of microsomal cytochrome P450 enzymes involved in the oxidation of xenobiotic chemicals in human and fetal livers and adult lungs. Drug Metab Dispos 24: 515-522.
28. Murray GI, Melvin WT, Greenlee WF, Burke MD, (2001) Regulation, function, and tissue-specific expression of cytochrome P450 CYP1B1. Annu Rev Pharmacol Toxicol 41: 297-316.
29. George J, Murray M, Byth K, Farrell GC, (1995) Differential alterations of cytochrome P450 proteins in livers from patients with severe chronic liver disease. Hepatology 21: 120-128.
30. Lindros KO, Oinonen T, Johansson I, Ingelman-Sundberg M, (1997) Selective centrilobular expression of the aryl hydrocarbon receptor in rat liver. J Pharmacol Exp Ther 280: 506-511.
31. Franc MA, Pohjanvirta R, Tuomisto J, Okey AB, (2001) In vivo up-regulation of aryl hydrocarbon receptor expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in a dioxin-resistant rat model. Biochem Pharmacol 62: 1565-1578.
32. Singh D, Kashyap A, Pandey RV, Saini KS, (2011) Novel advances in cytochrome P450 research. Drug Discov Today 16: 793-799.
33. Wang XW, Heegaard NH, Orum H, (2012) MicroRNAs in liver disease. Gastroenterology 142: 1431-1443.
34. George J, Liddle C, Murray M, Byth K, Farrell GC, (1995) Pre-translational regulation of cytochrome P450 genes is responsible for disease-specific changes of individual P450 enzymes among patients with cirrhosis. Biochem Pharmacol 49: 873-881.
35. Farrell G, (1999) Effects of disease on expression and regulation of CYPs. Mol Aspects Med 20: 55-70.
36. Verbeeck RK, (2008) Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 64: 1147-1161.